Skip to main content Help with accessibility Skip to main navigation

DAPAGLIFLOZIN tablets (Forxiga®▼) for treating chronic heart failure with preserved or mildly reduced ejection fraction

CCG Approval Status:

Date Added: 25 - Sep - 2023
Body System:

The Cheshire and Merseyside Area Prescribing Group recommends the prescribing of DAPAGLIFLOZIN tablets (Forxiga®▼) as an option for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults, following specialist recommendation, in accordance with NICE TA902.

NHS Cheshire and Merseyside APPROVED